List of Peptide Therapies Companies in Germany - 9

Berlin Cures was first to follow up on the scientific finding that there are a large number of diseases associated with pathological functional autoantibodies directed against G protein-couples receptors. Heart failure and Long Covid belong to this group of diseases. Our aptamer BC 007 can neutralize these autoantibodies and this is the reason why Berlin Cures has been working for decades to develop a product based on scientific findings that may help many suffering patients.

We are the Peptide Experts! JPT has a large peptide synthesis capacity, providing over 1 million peptides per year. We offer all possible peptide modifications such as macrocyclic peptides, phosphorylated peptides, labeled and tagged peptides, radioligands, isotope labeling and more. Made in Germany Global Support More than 20 Years of Expertise Ethical, Environmental & Health Standards Portfolio: Custom Peptides Our patented technologies in peptide libraries, pools, microarrays, and micro-scale synthesis set us apart as a leader in the field. From micro to large-scale synthesis, our state-of-the-art labs in Germany deliver peptides tailored to your needs. Modified Peptides We produce modified peptides such as long and stapled peptides, dyes, labeled and biotinylated peptides, PTMs, unique building blocks, conjugations, macrocyclic peptides and more. PepMix Peptide Pools Peptide pools for antigen-specific T-cell stimulation in immune monitoring, assay control, cell therapy development, T-cell expansion etc. In addition to custom PepMix peptide pools we have more than 500 PepMixes in stock, for example: Control Pools: CEFX, CEF, Actin, CMV pp65 … Viral Proteins of EBV, SARS-CoV-2, CMV, VZV, HPV … TAA: Prame, NY-ESO-1, MART-1, MAGE A … Clinical Peptides & Pools Our resulting Clinical Grade Peptides have been approved for a variety of clinical applications including immunotherapy and vaccine development, immune monitoring, and clinical proteomics. Please visit our website for more information! JPT Peptide Technologies GmbH Management: Aurélien Claeyssen, Jens Holstein, Dr. Sierk Poetting Volmerstr. 5 D- 12489 Berlin T: +49 30 6392 5500 peptide@jpt.com https://www.jpt.com/ Registration Court: Berlin / Amtsgericht Charlottenburg, HRB 92692 VAT identification number: DE 814044483 Imprint: https://www.jpt.com/support-contact/corporate/imprint/ Privacy Policy: https://www.jpt.com/support-contact/corporate/privacy-policy/

Therapeutic peptides with pristine safety against psychiatric and metabolic diseases and computational engine to cost-efficiently generate novel peptides for a wide range of indications.

NOXXON is a biopharmaceutical company that specializes in drug development in the healthcare sector.

We are a German biotech company with a dis­­­­tinctive strategy to fight cancer. Our three academic cancer projects have demonstrated clinical proof of concept and are ready for final development by pharma.

PEPperPRINT is an innovative biotech company from Heidelberg, Germany, and the leading provider of high density peptide and protein microarrays for antibody characterization or the fingerprint analysis of antibody responses from biological samples. The product and service portfolio was recently complemented by T cell epitope mapping and monitoring, making PEPperPRINT a one-stop solution provider for the fingerprint analysis of immune responses e.g. for epitope mapping, antibody biomarker discovery or the analysis of adverse immune effects. PEPperPRINT’s peptide microarrays and screening services have been used by researchers around the world with over 200 peer-reviewed publications.

Priavoid is a clinical stage drug development company based in Düsseldorf, Germany. Its therapeutic focus is on protein misfolding disorders in the area of neurodegeneration. Key component of Priavoid's technology is an anti-oligomeric or anti-prionic mode of action, that efficiently and effectively disassembles neurotoxic aggregates by using all-D-peptides.

Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company addressing high unmet medical needs in the areas of immuno-oncology and immunology, as well as viral, neurodegenerative and cardiometabolic diseases. Secarna’s mission is to maximize the performance and output of its proprietary LNAplus™ antisense oligonucleotide discovery platform, as well as to develop highly specific, safe, and efficacious best-in-class antisense therapies for challenging or currently undruggable targets. With over 15 development programs focusing on targets in indications where antisense-based approaches have clear benefits over other therapeutic modalities, Secarna is the leading European antisense drug discovery and development company.

Topas Therapeutics is a clinical-stage biotechnology company transforming the field of immune tolerance with a novel antigen-specific and targeted nanoparticle technology. Our antigen-coupled nanoparticle platform harnesses the tolerogenic power of the liver to treat autoimmune diseases. Our proprietary Topas Particles Conjugates target liver sinusoidal endothelial cells, a specific type of antigen-presenting cells highly effective at inducing T cell tolerance. With a technology adjustable to a broad spectrum of disease-relevant antigens, we have established a growing and advanced clinical pipeline to induce systemic tolerance. To learn more visit https://topas-therapeutics.com/